by 
The infectious disease therapeutics market involves developing and marketing pharmaceutical drugs and vaccines for treating infectious diseases such as hepatitis, HIV/AIDS, hospital-acquired infections, influenza, bacterial infections, tuberculosis and other parasitic diseases. Some key infectious disease treatments include antibiotics, antifungals, antivirals, vaccines, monoclonal antibodies and other biologics. Monoclonal antibody therapies are gaining significant adoption for treating infectious diseases due to advantages such as improved selectivity and less frequent dosing compared to conventional small molecule drugs. For instance, bezlotoxumab is a monoclonal antibody approved for reducing recurrence of Clostridium difficile infection.
The global infectious disease therapeutics Market is estimated to be valued at US$ 170.67 Bn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Growing adoption of monoclonal antibodies (as referenced in the heading) is one of the key drivers propelling the infectious disease therapeutics market growth. Monoclonal antibodies have emerged as an important class of biologics due to advantages such as high selectivity allowing targeted treatment with minimal side effects. For instance, palivizumab is a monoclonal antibody approved for reducing respiratory syncytial virus related hospitalization in infants. Moreover, recent advances in antibody engineering technologies such as bispecific T-cell engagers (BiTE) have facilitated development of novel and more effective antibody therapies. Another driver increasing the infectious disease therapeutics demand is rising global disease burden of infectious diseases such as AIDS, tuberculosis, malaria and influenza, especially in developing economies. According to the World Health Organization, tuberculosis remains one of the top 10 causes of death worldwide. Growing prevalence of antibiotic resistant bacterial and fungal pathogens is also fueling the need for development of novel anti-infective drugs with new mechanisms of action.
Segment Analysis
The infectious disease therapeutics market is segmented based on disease type, pathology, distribution channel and geography. The disease type segment is further divided into bacterial infection, viral infection, parasitic infection and fungal infection. Among these, the viral infection segment dominates the market currently due to the increasing prevalence of viral diseases like hepatitis, HIV/AIDS, influenza etc. The pathology segment is classified as immunological, genetic and others where immunological pathogens have the largest market share.
PEST Analysis
Political: Government initiatives to control infectious diseases and increased funding for R&D of new drugs and vaccines has positively impacted the market growth. Various regulatory approvals for new drug launches have also supported the market.
Economic: Rising per capita healthcare expenditure, growing demand for low-cost generic drugs and rising income levels in developing nations are driving the economic growth of this market.
Social: Increasing awareness regarding diseases, changing lifestyles leading to new infection emergence and globalization aiding disease spread are influencing the social factors.
Technological: Developments in drug delivery technologies, targeted drug therapies and biologics have expanded treatment options while PCR technologies have aided faster disease diagnosis and management.
Key Takeaways
The global infectious disease therapeutics market is expected to witness high growth over the forecast period of 2023 to 2030. The global infectious disease therapeutics Market is estimated to be valued at US$ 170.67 Bn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023 to 2030.
Regionally, North America currently captures the largest market share due to the growing incidences of infectious diseases and rapid adoption of advanced technologies. However, Asia Pacific is likely to experience the fastest growth rate owing to rising healthcare spending and increasing focus of key players in the region.
Key players operating in the infectious disease therapeutics market are Novartis International AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, F. Hoffmann-La Roche AG, BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH. Key players are involved in new drug development through organic and inorganic strategies like collaborations and acquisitions to strengthen their product pipelines and market position. They are also focusing on emerging markets through marketing initiatives to drive future sales.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
